Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralymphatic immunotherapy in increasing doses up to 10,000 SQ-U
2015-001259-63Phase 2Completed
- Sponsor
- Karolinska Institutet
- Start
- Apr 2015
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of allergenic extract of birch and Oralair in seasonal allergic rhinitis (SAR) (2 arms), sponsored by Karolinska Institutet. Primary endpoint: Total combined daily symptoms and medications score during peak pollen season. Started Apr 2015; status: completed.
02
Drugs
allergenic extract of birchOralair
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on 2015-001259-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001259-63.